Movement Alert|Charles River Laboratories Intraday Rise 5.04% in Regular Trading, $470 Million Frontage Asset Deal Lifts Shares

Market Focus11-10

On November 10, Charles River Laboratories rose 5.04% in Regular Trading, trading at $354.51 per share, with turnover of $84.50 million.

The move followed the company’s announcement that it agreed to acquire Frontage’s bioanalysis and drug metabolism and pharmacokinetics businesses in Exton, Pennsylvania for about $470 million in cash.

The transaction is tied to a broader privatization and delisting of Frontage by a consortium including Charles River Laboratories, Tigermed, and Frontage’s chairman, after which the targeted bioanalysis and DMPK assets are expected to be reorganized and fully taken over by Charles River Laboratories. The deal points to continued portfolio expansion after management previously said it had capacity and interest to pursue acquisitions, while also adding capabilities in services already central to its Discovery and Safety Assessment operations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment